Methods for treating antipsychotic-induced weight gain
AssigneeAlkermes Pharma Ireland Limited
InventorsDaniel Deaver, Mark Todtenkopf
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Claims12
A method of reducing diseases or disorders associated with the adverse metabolic profile of olanzapine by administering to a patient in need 10 thereof an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method of lowering circulating ghrelin levels in a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:
- or a pharmaceutically acceptable salt thereof.
A method of lowering circulating ghrelin levels in a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:
- or a pharmaceutically acceptable salt thereof, wherein said ghrelin level is increased by the administration of an atypical antipsychotic.
A method of lowering ghrelin levels in gastrointestinal tracts of a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:
- or a pharmaceutically acceptable salt thereof.
A method of lowering ghrelin levels in gastrointestinal tracts of a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:
- or a pharmaceutically acceptable salt thereof, wherein said ghrelin level is increased by the administration of an atypical antipsychotic.
Dependencies are inferred from the claim text.